{
  "functional_evidence_assessment": [
    {
      "variant_id": "EGFR L858R",
      "Gene": "Extracted_Gene_AAA",
      "Protein_Change": {
        "ref": "L",
        "alt": "R",
        "position": "858"
      },
      "variant_string_id": "EGFR L858R",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper clearly defines the pathogenic mutation of Y1699C in LRRK2, affecting its ROC-GTPase activity.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that Y1699C causes a pathogenic mutation and discusses dimerization effects on activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "General assays such as enzyme activity, protein interaction, and gene expression assays were appropriately described.",
          "judgment": "Yes",
          "reasoning": "The paper uses multiple assays relevant to the mutation's function."
        },
        {
          "step_name": "Step 3a: Basic controls and replicates",
          "extracted_paper_info": "Both 'Normal/Negative/Wild type' and 'Abnormal/Positive/Null' experiments were conducted, fulfilling the requirement for basic controls.",
          "judgment": "Yes",
          "reasoning": "The paper includes these experimental bases, indicating applicable general classes of assays."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The Y1699C mutation in LRRK2 primarily affects pathogenicity, supported by basic controls and dimerization effects."
    }
  ]
}